Outlook Sees Finish Line For Ophthalmic Bevacizumab
The US FDA Issued CRL Last Year Over CMC Issues And Lack Of Evidence
While a European decision is just around the corner, Outlook Therapeutics has more work to do in the US to convince the FDA about its bevacizumab product.
